Barclays Maintains Equal-Weight on Humacyte, Raises Price Target to $0.6

Benzinga · 1d ago
Barclays analyst Christopher Pasquale maintains Humacyte (NASDAQ:HUMA) with a Equal-Weight and raises the price target from $0.5 to $0.6.